Atrium Therapeutics receives FDA IND clearance for ATR 1072 in PRKAG2 syndrome; Phase 1/2 trial to start

Atrium Therapeutics, Inc.

• FDA cleared IND for ATR 1072, a precision cardiology RNA therapeutic for PRKAG2 syndrome.
• Corventis Phase 1/2 trial will enroll ~37 participants; first patient expected by end of 2026.
• Initial proof-of-concept data anticipated in second half of 2027.
• PRKAG2 syndrome is a rare genetic cardiomyopathy with no approved therapy addressing root cause.
• This is Atrium's first precision cardiology program to enter clinic.